In this World Pharma Today interview, Indero’s Chief Business Officer, Jason Shuris, reflects on how Contract Research Organizations (CROs) are evolving amid rapid changes in the life‑science industry.
Shuris also discusses how scientific leadership, consistency of delivery, and a clear therapeutic focus position Indero as a differentiated partner for sponsors. By applying lessons learned from dermatology—where precision, complex endpoints, and nuanced disease pathways are the norm—Indero aims to bring new depth and clarity to rheumatology trials.
